Adverum Biotechnologies Inc Stock

$2.46

5.02% yesterday

Nasdaq, Jun 13, 10:00 pm CET

ISIN

US00773U1088

Symbol

ADVM

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Biotechnology

Overview Dividends Analysts Charts News Strategies

Adverum Biotechnologies Inc Stock price

$2.46

-234.54 98.96% 5Y

Nasdaq, Closing price Fri, Jun 13 2025

-0.13 5.02%

ISIN

US00773U1088

Symbol

ADVM

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Biotechnology

Key metrics

Market capitalization	$54.11m
Enterprise Value	$-28.97m
EV/FCF (TTM) EV/FCF	0.26
P/B ratio (TTM) P/B ratio	2.03
Free Cash Flow (TTM) Free Cash Flow	$-112.51m
Cash position	$83.08m
P/E forward	negative
P/S forward	227.83
EV/Sales forward	negative
Short interest	10.61%

As a Free StocksGuide user, you can view scores for all 6,847 stocks worldwide.

Get Started for Free Today

Adverum Biotechnologies Inc Stock Analysis

Unlock Scores for Free

??

5 Analysts have issued a Adverum Biotechnologies Inc forecast:

4x Buy

80%

1x Hold

20%

More details on Analyst Estimates Including Price Targets

5 Analysts have issued a Adverum Biotechnologies Inc forecast:

Buy

80%

Hold

20%

Analyst Estimates with Stock Price Targets

Financial data from Adverum Biotechnologies Inc

Income Statement P&L | Balance Sheet | Cash Flow

Quarter TTM Annually

Dec '24		+/- %
Revenue	1 1	72% 72% 100%
- Direct Costs	- -	- -
Gross Profit	- -	- -
- Selling and Administrative Expenses	61 61	22% 22% 6,076%
- Research and Development Expense	77 77	1% 1% 7,704%
EBITDA	-133 -133	13% 13% -13,315%
- Depreciation and Amortization	3.65 3.65	35% 35% 365%
EBIT (Operating Income) EBIT	-137 -137	11% 11% -13,680%
Net Profit	-129 -129	10% 10% -12,857%

In millions USD.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Subscribe Now

Adverum Biotechnologies Inc Stock News

Neutral

GlobeNewsWire

●

8 days ago

Adverum Biotechnologies Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

REDWOOD CITY, Calif., June 05, 2025 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM) today announced that the Compensation Committee of Adverum's Board of Directors granted inducement awards consisting of non-qualified stock options to purchase 9,740 shares of common stock and restricted stock units (RSUs) for 4,870 shares of common stock to two new employees under Adverum's 201...

Neutral

GlobeNewsWire

●

about one month ago

Adverum Biotechnologies Reports First Quarter 2025 Financial Results and Provides Pipeline Highlights

- Initiated ARTEMIS, the first-ever registrational intravitreal gene therapy trial, in both treatment-experienced and treatment-naive patients with wet AMD - Presented the first human data mapping cell-level transduction and aflibercept mRNA expression 3.5 years after Ixo-vec administration, establishing the potential for life-long vision preservation REDWOOD CITY, Calif., May 14, 2025 (GLOB...

Neutral

GlobeNewsWire

●

about one month ago

Adverum Biotechnologies Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

REDWOOD CITY, Calif., May 02, 2025 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM) today announced that the Compensation Committee of Adverum's Board of Directors granted inducement awards consisting of non-qualified stock options to purchase 32,620 shares of common stock and restricted stock units (RSUs) for 16,310 shares of common stock to seven new employees under Adverum's ...

More Adverum Biotechnologies Inc News

Company Profile

Adverum Biotechnologies, Inc. is a clinical-stage biotechnology company that engages in the development of novel gene therapies to treat patients with sight-threatening ophthalmic diseases. It focuses on treatment of wet age-related macular degeneration, alpha-1 antitrypsin deficiency, hereditary angioedema, friedreich's ataxia, severe allergy, color vision deficiency, and juvenile x-linked retinoschisis. The company was founded by Mark S. Blumenkranz, Thomas W. Chalberg, Jr., Mitchell H. Finer and Steven Daniel Schwartz on July 17, 2006 and is headquartered in Menlo Park, CA.

Head office	United States
CEO	Laurent Fischer
Employees	155
Founded	2006
Website	adverum.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now